ELEV
Price
$0.36
Change
-$0.00 (-0.00%)
Updated
Jul 22 closing price
Capitalization
21.63M
10 days until earnings call
XBIO
Price
$3.60
Change
-$0.04 (-1.10%)
Updated
Jul 25 closing price
Capitalization
5.56M
Interact to see
Advertisement

ELEV vs XBIO

Header iconELEV vs XBIO Comparison
Open Charts ELEV vs XBIOBanner chart's image
Elevation Oncology
Price$0.36
Change-$0.00 (-0.00%)
Volume$4.82M
Capitalization21.63M
Xenetic Biosciences
Price$3.60
Change-$0.04 (-1.10%)
Volume$88.58K
Capitalization5.56M
ELEV vs XBIO Comparison Chart in %
Loading...
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELEV vs. XBIO commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELEV is a Hold and XBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ELEV: $0.37 vs. XBIO: $3.60)
Brand notoriety: ELEV and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELEV: 270% vs. XBIO: 95%
Market capitalization -- ELEV: $21.63M vs. XBIO: $5.56M
ELEV [@Biotechnology] is valued at $21.63M. XBIO’s [@Biotechnology] market capitalization is $5.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELEV’s FA Score shows that 1 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • ELEV’s FA Score: 1 green, 4 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than ELEV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELEV’s TA Score shows that 2 TA indicator(s) are bullish while XBIO’s TA Score has 3 bullish TA indicator(s).

  • ELEV’s TA Score: 2 bullish, 4 bearish.
  • XBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ELEV and XBIO are a bad buy in the short-term.

Price Growth

ELEV (@Biotechnology) experienced а -2.67% price change this week, while XBIO (@Biotechnology) price change was -1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ELEV is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELEV($21.6M) has a higher market cap than XBIO($5.56M). XBIO YTD gains are higher at: -9.687 vs. ELEV (-35.123). XBIO has higher annual earnings (EBITDA): -3.88M vs. ELEV (-41.4M). ELEV has more cash in the bank: 80.7M vs. XBIO (5.16M). XBIO has less debt than ELEV: XBIO (153K) vs ELEV (31.3M). XBIO has higher revenues than ELEV: XBIO (2.58M) vs ELEV (0).
ELEVXBIOELEV / XBIO
Capitalization21.6M5.56M389%
EBITDA-41.4M-3.88M1,067%
Gain YTD-35.123-9.687363%
P/E RatioN/AN/A-
Revenue02.58M-
Total Cash80.7M5.16M1,563%
Total Debt31.3M153K20,458%
FUNDAMENTALS RATINGS
XBIO: Fundamental Ratings
XBIO
OUTLOOK RATING
1..100
97
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELEVXBIO
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 25 days ago
86%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ELEV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SONO11.25-0.03
-0.27%
Sonos
KE18.67-0.11
-0.59%
Kimball Electronics
XNET4.95-0.04
-0.80%
Xunlei Limited
INM2.64-0.04
-1.49%
InMed Pharmaceuticals Inc
DOC17.60-1.27
-6.73%
Healthpeak Properties

ELEV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELEV has been loosely correlated with TBPH. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ELEV jumps, then TBPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELEV
1D Price
Change %
ELEV100%
N/A
TBPH - ELEV
38%
Loosely correlated
-0.90%
AUTL - ELEV
30%
Poorly correlated
-4.55%
AKBA - ELEV
28%
Poorly correlated
-7.29%
ADAP - ELEV
28%
Poorly correlated
+19.62%
PYPD - ELEV
28%
Poorly correlated
-1.60%
More

XBIO and

Correlation & Price change

A.I.dvisor tells us that XBIO and NKTR have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and NKTR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-1.00%
NKTR - XBIO
27%
Poorly correlated
+1.71%
ELEV - XBIO
27%
Poorly correlated
N/A
VERA - XBIO
27%
Poorly correlated
-0.32%
ALT - XBIO
26%
Poorly correlated
N/A
CGEN - XBIO
24%
Poorly correlated
-0.65%
More